Biogen’s top scientist nearly dares FDA not to approve Alzheimer’s drug
Biogen’s top scientist offered unflinching support Thursday for the efficacy of the company’s controversial Alzheimer’s drug called aducanumab, shrugging off outside skepticism and almost daring regulators not to approve it.
“I believe the drug works,” said Al Sandrock, Biogen’s head of research and development and chief medical officer, speaking at the STAT Summit. “I’m very excited about the prospect of getting the drug approved.”
Read Original Article: Biogen’s top scientist nearly dares FDA not to approve Alzheimer’s drug »
